Planned Solutions Inc. Purchases 1,435 Shares of Pfizer Inc. (NYSE:PFE)

Planned Solutions Inc. lifted its position in shares of Pfizer Inc. (NYSE:PFEGet Rating) by 31.0% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 6,063 shares of the biopharmaceutical company’s stock after purchasing an additional 1,435 shares during the quarter. Planned Solutions Inc.’s holdings in Pfizer were worth $318,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in PFE. Norges Bank bought a new position in shares of Pfizer during the fourth quarter worth $3,351,891,000. Capital International Investors lifted its position in Pfizer by 3,059.6% in the 1st quarter. Capital International Investors now owns 38,530,003 shares of the biopharmaceutical company’s stock valued at $1,994,698,000 after acquiring an additional 37,310,556 shares in the last quarter. Vanguard Group Inc. lifted its position in Pfizer by 3.0% in the 1st quarter. Vanguard Group Inc. now owns 479,065,273 shares of the biopharmaceutical company’s stock valued at $24,801,210,000 after acquiring an additional 13,790,348 shares in the last quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main lifted its position in Pfizer by 577.8% in the 4th quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 12,247,903 shares of the biopharmaceutical company’s stock valued at $715,270,000 after acquiring an additional 10,440,786 shares in the last quarter. Finally, Massachusetts Financial Services Co. MA lifted its position in Pfizer by 28.2% in the 1st quarter. Massachusetts Financial Services Co. MA now owns 43,391,119 shares of the biopharmaceutical company’s stock valued at $2,246,359,000 after acquiring an additional 9,537,621 shares in the last quarter. 67.90% of the stock is owned by institutional investors.

Pfizer Stock Performance

NYSE PFE opened at $44.57 on Friday. The company has a quick ratio of 1.20, a current ratio of 1.42 and a debt-to-equity ratio of 0.39. The company has a market capitalization of $250.14 billion, a P/E ratio of 8.72, a P/E/G ratio of 0.54 and a beta of 0.70. Pfizer Inc. has a 12-month low of $40.94 and a 12-month high of $61.71. The firm has a 50-day moving average price of $48.40 and a two-hundred day moving average price of $50.33.

Pfizer (NYSE:PFEGet Rating) last posted its quarterly earnings data on Thursday, July 28th. The biopharmaceutical company reported $2.04 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.95 by $0.09. The firm had revenue of $27.74 billion during the quarter, compared to the consensus estimate of $26.20 billion. Pfizer had a net margin of 28.92% and a return on equity of 43.18%. The business’s revenue for the quarter was up 46.8% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.07 EPS. Analysts anticipate that Pfizer Inc. will post 6.54 earnings per share for the current year.

Pfizer Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, December 5th. Stockholders of record on Friday, November 4th will be issued a dividend of $0.40 per share. This represents a $1.60 dividend on an annualized basis and a dividend yield of 3.59%. Pfizer’s dividend payout ratio (DPR) is presently 31.31%.

Analysts Set New Price Targets

Several equities research analysts recently commented on the stock. Berenberg Bank set a $44.00 price objective on shares of Pfizer in a research report on Wednesday, September 14th. JPMorgan Chase & Co. set a $57.00 price target on shares of Pfizer in a research note on Tuesday, June 28th. UBS Group set a $59.00 price target on shares of Pfizer in a research note on Thursday, September 1st. SVB Leerink lowered their price target on shares of Pfizer from $55.00 to $53.00 and set a “market perform” rating on the stock in a research note on Friday, July 29th. Finally, The Goldman Sachs Group set a $50.00 price target on shares of Pfizer in a research note on Thursday, September 1st. Nine research analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $57.00.

Pfizer Company Profile

(Get Rating)

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands.

Read More

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFEGet Rating).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.